Alexion Pharmaceuticals Inc (NASDAQ:ALXN) - Share price

Stock Report

Alexion Pharmaceuticals Inc ALXN

Income Statement
Cost of Revenue233.09258.00454.20374.30394.50
Gross Operating Profit2,370.962,826.003,096.903,756.904,596.60
Operating expenses
Research and development709.47757.00878.40730.40886.00
Sales, general and administrative862.60954.001,094.401,111.801,261.10
Staff cost-----
Depreciation and amortization116.58322.00320.10320.10309.60
Other Operating Expenses0.
Total Operating Expenses1,688.652,033.002,292.902,162.302,456.70
Operating income before interest and taxes682.31793.00804.001,594.602,139.90
Non-operating income-184.17-217.00-256.20-1,352.4038.90
Income before income taxes498.14576.00547.80242.202,178.80
Provision for income taxes353.76177.00104.50164.60-225.50
Net income from continuing operations144.39399.00443.3077.602,404.30
Net Income144.39399.00443.3077.602,404.30
Net income available for common shareholders144.39399.00443.3077.602,404.30
Earnings per share

Figures in millions. Currency is USD.

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2020 Morningstar. All rights reserved.